topic

222-L Pemigatinib increases the effectiveness of EpCAM-CAR-T in squamous cell carcinoma
Jyothi Thyagabhavan Mony, Xiaoyu Zhang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1782; DOI: 10.1136/jitc-2023-SITC2023.0222-L
222-M A new ELISpot/FluoroSpot best practice using a novel lyophilized FBS for clinical immune monitoring assays
Elizabeth A Reap

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1783; DOI: 10.1136/jitc-2023-SITC2023.0222-M
222-N Analysis of pathologic features and efficacy outcomes with neoadjuvant nivolumab plus platinum-doublet chemotherapy for resectable non-small cell lung cancer in CheckMate 816
Julie Stein Deutsch, Ashley Cimino-Mathews, Elizabeth Thompson, Mariano Provencio, Patrick M Forde, Jonathan Spicer, Nicolas Girard, Daphne Wang, Robert A Anders, Edward Gabrielson, Peter Illei, Jaroslaw Jedrych, Ludmila Danilova, Joel Sunshine, Keith M Kerr, Mia Tran, Judy Bushong, Junliang Cai, Vipul Devas, Jaclyn Neely, David Balli, Tricia R Cottrell, Alex S Baras, Janis Taube

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1784; DOI: 10.1136/jitc-2023-SITC2023.0222-N
442-A Optimization and validation of novel chimeric antigen receptor (CARs) architectures for the treatment of leukemia and beyond
Etienne Gagnon, Margaux Tual

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1785; DOI: 10.1136/jitc-2023-SITC2023.0442-A
442-B IL-18-enhanced non-activated CAR T-cells for improved metabolic function and therapeutic efficacy
Joseph Durgin, Ashwin Sannecy, Nandana Mukherjee, Xiaoling Jin, Andre Kelly, Alexander Shestov, Jakub Svoboda, Joseph A Fraietta, Carl H June, Roddy O’Connor, Saba Ghassemi

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1786; DOI: 10.1136/jitc-2023-SITC2023.0442-B
442-C A best-in-class HSC-derived CAR-Monocyte product with a novel CAR costimulatory domain significantly improves CAR-M activity against solid tumors
Kilsoo Jeon, Grace Reynolds, Anastasya Birger, Beatrice Breckheimer, Jessica Pafford, Matthew Esquivel, Adam Pecoraro, Warren Anderson, Kevin Carbajal, Sumiti Jain

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1787; DOI: 10.1136/jitc-2023-SITC2023.0442-C
442-D OUTLAST™ CAR-T cells exhibit superior effector function against solid tumors
Warren Anderson, Prasanna Ekambaram, Jessica Pafford, Matthew Esquivel, Adam Pecoraro, Kevin Carbajal, Sumiti Jain

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1788; DOI: 10.1136/jitc-2023-SITC2023.0442-D
442-E A novel targeted, type I interferon producing, innate lymphocyte therapy with potent anti-tumor activity
Anders Laustsen, Tobias W Bjerg, Aida S Hansen, Ditte Jæhger, Trine I Jensen, Mette-Louise Trempenau, Kasper M Jensen, Nicolai O Haahr, Marcus N Rosendal, Jonas B Vejlebo, Iulia Diaconu, Rasmus O Bak, Martin R Jakobsen

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1789; DOI: 10.1136/jitc-2023-SITC2023.0442-E
442-F Optimization of a human scFv-based PSMA-CAR T cell therapy for the treatment of metastatic castration-resistant prostate cancer
Lupita S Lopez, Jason Yang, Ziyou Cui, Wen-Chung Chang, Vivien Chan, Saul Priceman

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1790; DOI: 10.1136/jitc-2023-SITC2023.0442-F
442-G Metabolic reprogramming regulates anti-tumor effects of engineered CAR/TCR T cells
Rashmi Pillai, Xiaoyu Zhang, Yama Abassi

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1791; DOI: 10.1136/jitc-2023-SITC2023.0442-G

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages